BCR-ABL allosteric inhibitor

This page covers all BCR-ABL allosteric inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting BCR-ABL.

Targets

BCR-ABL

Phase 3 pipeline (1)

• ABL001 · Marlise Luskin, MD · Oncology
  ABL001 is an allosteric inhibitor of BCR-ABL that binds to a pocket distinct from the ATP-binding site, allowing it to overcome certain resistance mutations.